CERENO SCIENTIFIC AB B (F:4A1) — Market Cap & Net Worth
Market Cap & Net Worth: CERENO SCIENTIFIC AB B (4A1)
CERENO SCIENTIFIC AB B (F:4A1) has a market capitalization of $183.50 Million (€156.96 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #16865 globally and #1591 in its home market, demonstrating a -2.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CERENO SCIENTIFIC AB B's stock price €0.54 by its total outstanding shares 295194861 (295.19 Million).
CERENO SCIENTIFIC AB B Market Cap History: 2021 to 2026
CERENO SCIENTIFIC AB B's market capitalization history from 2021 to 2026. Data shows growth from $160.65 Million to $184.98 Million (13.62% CAGR).
CERENO SCIENTIFIC AB B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CERENO SCIENTIFIC AB B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4A1 by Market Capitalization
Companies near CERENO SCIENTIFIC AB B in the global market cap rankings as of May 2, 2026.
Key companies related to CERENO SCIENTIFIC AB B by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
CERENO SCIENTIFIC AB B Historical Marketcap From 2021 to 2026
Between 2021 and today, CERENO SCIENTIFIC AB B's market cap moved from $160.65 Million to $ 184.98 Million, with a yearly change of 13.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €184.98 Million | -15.59% |
| 2025 | €219.15 Million | +38.53% |
| 2024 | €158.20 Million | +3.01% |
| 2023 | €153.58 Million | +154.87% |
| 2022 | €60.26 Million | -62.49% |
| 2021 | €160.65 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of CERENO SCIENTIFIC AB B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $183.50 Million USD |
| MoneyControl | $183.50 Million USD |
| MarketWatch | $183.50 Million USD |
| marketcap.company | $183.50 Million USD |
| Reuters | $183.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more